Fertility, pregnancy and delivery in women after biventricular repair for double outlet right ventricle

Objectives: To investigate outcome of pregnancy and fertility in women with double outlet right ventricle (DORV). Methods: Using 2 congenital heart disease registries, 21 female patients with DORV (aged 18-39 years) were retrospectively identified. Detailed recordings of each patient and their completed (>20 weeks gestation) pregnancies were recorded. Results: Overall, 10 patients had 19 pregnancies, including 3 spontaneous miscarriages (16%). During the 16 live birth pregnancies, primarily (serious) noncardiac complications were observed, e.g. premature labor/delivery (n = 7 and n = 3, respectively), small for gestational age (n = 4), preeclampsia (n = 2) and recurrence of congenital heart disease (n = 2). Except for postpartum endocarditis and deterioration of subpulmonary obstruction, only mild cardiac complication pregnancies were recorded. Two women with children reported secondary female infertility. Several menstrual cycle disorders were reported: secondary amenorrhea (n = 4), primary amenorrhea (n = 3) and oligomenorrhea (n = 2). Conclusion: Successful pregnancy in women with DORV is possible. Primarily noncardiac complications were observed and only few (minor) cardiac complications. Infertility and menstrual cycle disorders appear to be more prevalent. Copyrigh

Second intravenous immunoglobulin dose in patients with Guillain-Barre syndrome with poor prognosis (SID-GBS):a double-blind, randomised, placebo-controlled trial

Background Treatment with one standard dose (2 g/kg) of intravenous immunoglobulin is insufficient in a proportion of patients with severe Guillain-Barre syndrome. Worldwide, around 25% of patients severely affected with the syndrome are given a second intravenous immunoglobulin dose (SID), although it has not been proven effective. We aimed to investigate whether a SID is effective in patients with Guillain-Barre syndrome with a predicted poor outcome. Methods In this randomised, double-blind, placebo-controlled trial (SID-GBS), we included patients (>= 12 years) with Guillain-Barre syndrome admitted to one of 59 participating hospitals in the Netherlands. Patients were included on the first day of standard intravenous immunoglobulin treatment (2 g/kg over 5 days). Only patients with a poor prognosis (score of >= 6) according to the modified Erasmus Guillain-Barre syndrome Outcome Score were randomly assigned, via block randomisation stratified by centre, to SID (2 g/kg over 5 days) or to placebo, 7-9 days after inclusion. Patients, outcome adjudicators, monitors, and the steering committee were masked to treatment allocation. The primary outcome measure was the Guillain-Barre syndrome disability score 4 weeks after inclusion. All patients in whom allocated trial medication was started were included in the modified intention-to-treat analysis. Findings Between Feb 16, 2010, and June 5, 2018, 327 of 339 patients assessed for eligibility were included. 112 had a poor prognosis. Of those, 93 patients with a poor prognosis were included in the modified intention-to-treat analysis: 49 (53%) received SID and 44 (47%) received placebo. The adjusted common odds ratio for improvement on the Guillain-Barre syndrome disability score at 4 weeks was 1.4 (95% CI 0.6-3.3; p=0.45). Patients given SID had more serious adverse events (35% vs 16% in the first 30 days), including thromboembolic events, than those in the placebo group. Four patients died in the intervention group (13-24 weeks after randomisation). Interpretation Our study does not provide evidence that patients with Guillain-Barre syndrome with a poor prognosis benefit from a second intravenous immunoglobulin course; moreover, it entails a risk of serious adverse events. Therefore, a second intravenous immunoglobulin course should not be considered for treatment of Guillain-Barre syndrome because of a poor prognosis. The results indicate the need for treatment trials with other immune modulators in patients severely affected by Guillain-Barre syndrome. Funding Prinses Beatrix Spierfonds and Sanquin Plasma Products. Copyright (C) 2021 Elsevier Ltd. All rights reserved

Pregnancy and delivery in women with congenital heart disease

Tijdens een zwangerschap vinden er aanpassingen plaats die het lichaam van de moeder in staat stellen de ontwikkeling van de foetus te waarborgen. Het hart van de moeder zal (o.a. door toename van het bloedvolume) gedurende de zwangerschap meer arbeid moeten verrichten. Het is dan ook niet geheel vanzelfsprekend dat vrouwen die een aangeboren hartziekte hebben een zwangerschap zonder problemen kunnen doorstaan. UMCG-promovendus Willem Drenthen onderzocht welke complicaties vrouwen met aangeboren hartziekten tijdens hun zwangerschap en bevalling ontwikkelen. De belangrijkste bevinding in het onderzoek is de relatief hoge sterfte tijdens het eerste levensjaar onder nakomelingen van vrouwen met aangeboren hartziekten. In vergelijking met gezonde vrouwen lijken vrouwen met aangeboren hartziekten bovendien vaker een miskraam te krijgen. Ook ontwikkelen de moeders vaker een hartprobleem (o.a. hartritmestoornissen en hartfalen) waarvoor behandeling noodzakelijk is, wordt hun baby vaker te vroeg geboren, is hun baby vaker te klein voor de zwangerschapsduur en heeft ook de baby vaker een aangeboren hartziekte. Bovendien lijken de moeders vaker zwangerschaps-hoge bloeddruk danwel zwangerschapsvergiftiging op te lopen. Drenthen adviseert voor vrouwen met een aangeboren hartziekte een multidisciplinaire begeleiding tijdens zwangerschap en bevalling.

Aldosterone antagonists in the treatment of patients with left ventricular dysfunction

PART OF What Does It Mean To Be a Libertarian